Latest Innovation News

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

BlueBet Holdings has delivered positive EBITDA for the first half of FY25 ahead of schedule, driven by strategic customer reactivation and enhanced platform efficiencies following its merger with betr.

Mad Paws Holdings Limited has reported a strong Q2 FY25 with a 328% increase in cash EBITDA and a 16% rise in marketplace revenue, driven by a strategic above-the-line marketing campaign.

Zip Co Limited has posted record-breaking second quarter results for FY25, driven by exceptional holiday trading and robust growth in the US and ANZ markets. The company reported a 24.8% increase in Total Transaction Volume and a 50.2% rise in cash EBTDA.

Credit Corp Group reported steady H1 FY25 results with operational improvements and confirmed full-year guidance, driven by growth in US debt buying and stable Australian/New Zealand lending.

Credit Corp Group has reported a robust 32% rise in underlying NPAT for H1 FY2025, driven by strong US collections and consumer lending growth, while reaffirming its full-year guidance and announcing a healthy interim dividend.

LTR Pharma reports compelling clinical results for its nasal spray ED treatment SPONTAN®, demonstrating rapid absorption and strong safety, alongside strategic partnerships and a robust $34 million cash position.

RMA Global Limited has reported its first cash flow positive quarter since listing, alongside a 9% revenue increase driven by strong US and ANZ market performance and the strategic acquisition of Curated Social.

MyEco Group Ltd has reported a robust 32% increase in sustainable product sales for Q2 FY25, driven by a remarkable 156% jump in MyEco branded product sales. Despite negative operating cash flow due to inventory build-up, the company is poised for continued growth in the second half of the fiscal year.

Beforepay Group has reported a strong Q2 FY25 with record revenue exceeding $10 million and a growing active user base, while introducing its new Personal Loan product.

Bio-Gene Technology Limited has advanced its bio-insecticide pipeline with two U.S. Department of Defense grants totaling A$3 million, alongside key regulatory and production milestones for Flavocide® and Qcide®.

Biome Australia Limited has announced encouraging results from functional studies on its probiotic strain BMB18, highlighting its potential to modulate immune responses, reduce inflammation, and support intestinal health. These findings pave the way for targeted clinical research and product innovation.